Document is current
Any future updates will be listed below
-
Authors
Spudich, James A https://orcid.org/0000-0002-4324-4254
Nandwani, Neha https://orcid.org/0000-0002-6958-3756
Robert-Paganin, Julien https://orcid.org/0000-0001-6102-2025
Houdusse, Anne https://orcid.org/0000-0002-8566-0336
Ruppel, Kathleen M https://orcid.org/0000-0002-0971-5331
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute of General Medical Sciences (R01GM33289)
HHS | NIH | National Institute of General Medical Sciences (RM1GM131981-01)
HHS | NIH | National Institute of General Medical Sciences (RM1GM131981-01)
Agence Nationale de la Recherche (ANR-21-CE11-0022-01)
American Heart Association (22POST908934)
- License Information
-
More Information
Article History
Received: 23 April 2024
Revised: 12 July 2024
Accepted: 18 July 2024
First Online: 27 August 2024
Disclosure and competing interests statement
: JAS is cofounder and on the Scientific Advisory Board of Cytokinetics, Inc., a company developing small molecule therapeutics for treatment of hypertrophic cardiomyopathy. JAS is cofounder and Executive Chairman, and KMR is cofounder & Research and Clinical Advisor, of Kainomyx, Inc., a company developing small molecule therapeutics targeting myosins in parasites. AH receives research funding from Cytokinetics and consults for Kainomyx.
